SG11201706349YA - Cysteine protease - Google Patents
Cysteine proteaseInfo
- Publication number
- SG11201706349YA SG11201706349YA SG11201706349YA SG11201706349YA SG11201706349YA SG 11201706349Y A SG11201706349Y A SG 11201706349YA SG 11201706349Y A SG11201706349Y A SG 11201706349YA SG 11201706349Y A SG11201706349Y A SG 11201706349YA SG 11201706349Y A SG11201706349Y A SG 11201706349YA
- Authority
- SG
- Singapore
- Prior art keywords
- cysteine protease
- cysteine
- protease
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6472—Cysteine endopeptidases (3.4.22)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6472—Cysteine endopeptidases (3.4.22)
- C12N9/6475—Interleukin 1-beta convertase-like enzymes (3.4.22.10; 3.4.22.36; 3.4.22.63)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/22—Cysteine endopeptidases (3.4.22)
- C12Y304/2201—Streptopain (3.4.22.10)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Oncology (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201502305A GB201502305D0 (en) | 2015-02-12 | 2015-02-12 | Protein |
| PCT/EP2016/053054 WO2016128559A1 (en) | 2015-02-12 | 2016-02-12 | Cysteine protease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201706349YA true SG11201706349YA (en) | 2017-09-28 |
Family
ID=52781455
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201706349YA SG11201706349YA (en) | 2015-02-12 | 2016-02-12 | Cysteine protease |
Country Status (28)
| Country | Link |
|---|---|
| US (3) | US10758597B2 (en) |
| EP (2) | EP3256579B1 (en) |
| JP (1) | JP6879921B2 (en) |
| KR (1) | KR102524594B1 (en) |
| CN (2) | CN107532158A (en) |
| AU (1) | AU2016217801B2 (en) |
| BR (1) | BR112017017286A2 (en) |
| CA (1) | CA2976016C (en) |
| CL (1) | CL2017002066A1 (en) |
| CO (1) | CO2017009060A2 (en) |
| DK (1) | DK3256579T3 (en) |
| EA (1) | EA035896B1 (en) |
| ES (1) | ES2962794T3 (en) |
| FI (1) | FI3256579T3 (en) |
| GB (1) | GB201502305D0 (en) |
| HR (1) | HRP20231496T1 (en) |
| HU (1) | HUE064122T2 (en) |
| IL (1) | IL253939B (en) |
| LT (1) | LT3256579T (en) |
| MX (1) | MX2017010389A (en) |
| MY (1) | MY187486A (en) |
| PL (1) | PL3256579T3 (en) |
| PT (1) | PT3256579T (en) |
| RS (1) | RS64840B1 (en) |
| SG (1) | SG11201706349YA (en) |
| SI (1) | SI3256579T1 (en) |
| WO (1) | WO2016128559A1 (en) |
| ZA (1) | ZA201705114B (en) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201502305D0 (en) | 2015-02-12 | 2015-04-01 | Hansa Medical Ab | Protein |
| GB201502306D0 (en) | 2015-02-12 | 2015-04-01 | Hansa Medical Ab | Protein |
| US20210228738A1 (en) | 2017-07-17 | 2021-07-29 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins |
| CN108410798A (en) * | 2018-03-27 | 2018-08-17 | 福建三造血技术有限公司 | Cell separation microballon eluent and preparation method |
| EP3774854A1 (en) | 2018-04-03 | 2021-02-17 | Stridebio, Inc. | Antibody-evading virus vectors |
| WO2020102740A2 (en) * | 2018-11-16 | 2020-05-22 | Spark Therapeutics, Inc. | Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins |
| CA3127950A1 (en) * | 2019-01-28 | 2020-08-06 | Duke University | Compositions and methods for evading humoral immunity |
| TW202102525A (en) | 2019-03-21 | 2021-01-16 | 美商史崔德生物公司 | Recombinant adeno-associated virus vectors |
| US20220347298A1 (en) | 2019-10-04 | 2022-11-03 | Ultragenyx Pharmaceutical Inc. | Methods for improved therapeutic use of recombinant aav |
| MX2022004352A (en) | 2019-10-17 | 2022-07-19 | Stridebio Inc | Adeno-associated viral vectors for treatment of niemann-pick disease type c. |
| BR112021025438A2 (en) | 2019-12-06 | 2022-06-21 | Regeneron Pharma | Anti-vegf protein compositions and methods for producing the same |
| KR20220161268A (en) * | 2020-01-22 | 2022-12-06 | 스파크 테라퓨틱스, 인코포레이티드 | Compositions and methods for increasing or enhancing transduction of gene therapy vectors and removing or reducing immunoglobulins |
| GB202002072D0 (en) | 2020-02-14 | 2020-04-01 | Hansa Biopharma AB | immunoglobulin detection and associated therapies |
| KR20220140537A (en) | 2020-02-14 | 2022-10-18 | 울트라제닉스 파마수티컬 인코포레이티드 | Gene therapy to treat CDKL5 deficiency disorder |
| GB202003129D0 (en) | 2020-03-04 | 2020-04-15 | Hansa Biopharma AB | Conditioning regimen for transplant of stem cells |
| GB202007434D0 (en) | 2020-05-19 | 2020-07-01 | Hansa Biopharma AB | Methods |
| WO2021244628A1 (en) | 2020-06-05 | 2021-12-09 | 上海宝济药业有限公司 | Pharmaceutical composition of enzymes and viruses and application thereof |
| EP4215208A1 (en) * | 2020-09-21 | 2023-07-26 | Shanghai Bao Pharmaceuticals Co., Ltd. | Pharmaceutical combination and use thereof |
| US20230374542A1 (en) | 2020-10-07 | 2023-11-23 | Asklepios Biopharmaceutical, Inc. | Therapeutic adeno-associated virus delivery of fukutin related protein (fkrp) for treating dystroglycanopathy. disorders including limb girdle 21 (lgmd21) |
| WO2022221529A1 (en) | 2021-04-16 | 2022-10-20 | Asklepios Biopharmaceutical, Inc. | Rational polyploid aav virions that cross the blood brain barrier and elicit reduced humoral response |
| EP4079848A1 (en) | 2021-04-22 | 2022-10-26 | Genovis Ab | Immunoglobulin cleaving enzyme |
| FR3125965A1 (en) * | 2021-08-05 | 2023-02-10 | Mc Saf | Antibody-drug conjugates |
| WO2023019168A1 (en) | 2021-08-11 | 2023-02-16 | Ultragenyx Pharmaceutical Inc. | Compositions and methods for treating a muscular dystrophy |
| WO2023084095A2 (en) | 2021-11-15 | 2023-05-19 | Hansa Biopharma AB | Methods for enhancing adoptive cell transfer immunotherapies |
| EP4275701A1 (en) | 2022-05-13 | 2023-11-15 | Hansa Biopharma AB | Conditioning regimen for cell transplant |
| EP4302770A1 (en) | 2022-07-08 | 2024-01-10 | Hansa Biopharma AB | Regimen for enzymatic desensitisation |
| WO2024057095A1 (en) | 2022-09-14 | 2024-03-21 | Genovis Ab | Mutant protease |
| EP4349365A1 (en) | 2022-10-07 | 2024-04-10 | Hansa Biopharma AB | Co-treatment for gene therapy |
| CN115873833A (en) * | 2022-11-08 | 2023-03-31 | 上海泰昶生物技术有限公司 | Engineering strain and process for producing immunoglobulin G degrading enzyme |
| CN115998690A (en) * | 2022-11-10 | 2023-04-25 | 上海泰昶生物技术有限公司 | Freeze-dried preparation containing immunoglobulin G degrading enzyme and preparation process thereof |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
| CA2421278A1 (en) * | 1998-03-11 | 1999-09-16 | Genentech, Inc. | Novel polypeptides and nucleic acids encoding the same |
| AU1686302A (en) | 2000-12-21 | 2002-07-01 | Shire Biochem Inc | Streptococcus pyogenes antigens and corresponding dna fragments |
| GB0130228D0 (en) | 2001-12-18 | 2002-02-06 | Hansa Medica Ab | Protein |
| EP1901773B1 (en) * | 2005-06-09 | 2012-03-07 | Hansa Medical AB | Use of the ides proteinase (from s. pyogenes) for treating autoimmune diseases and graft rejection |
| GB0511769D0 (en) * | 2005-06-09 | 2005-07-20 | Hansa Medical Ab | Treatment |
| GB0624874D0 (en) * | 2006-12-13 | 2007-01-24 | Hansa Medical Ab | Treatment |
| US8323908B2 (en) | 2007-09-14 | 2012-12-04 | Genovis Ab | Method of assessing glycosylation state or functional quality of an IgG containing sample |
| WO2009075646A1 (en) | 2007-12-13 | 2009-06-18 | Bengt Guss | Improved immunizing composition |
| CA2709029A1 (en) | 2007-12-21 | 2009-07-02 | Bianca Eser | Stability testing of antibodies |
| WO2010089126A2 (en) | 2009-02-09 | 2010-08-12 | Roche Glycart Ag | Immunoglobulin glycosylation pattern analysis |
| WO2011149419A1 (en) * | 2010-05-26 | 2011-12-01 | Intervacc Ab | Vaccine against streptococcal infections based on recombinant proteins |
| GB201115841D0 (en) * | 2011-09-13 | 2011-10-26 | Genovis Ab | Protein and method |
| GB201201314D0 (en) | 2012-01-26 | 2012-03-07 | Isis Innovation | Composition |
| GB201316744D0 (en) | 2013-09-20 | 2013-11-06 | Genovis Ab | Method |
| GB201413240D0 (en) | 2014-07-25 | 2014-09-10 | Hansa Medical Ab | Method |
| GB201502305D0 (en) | 2015-02-12 | 2015-04-01 | Hansa Medical Ab | Protein |
| GB201502306D0 (en) | 2015-02-12 | 2015-04-01 | Hansa Medical Ab | Protein |
| US20210228738A1 (en) * | 2017-07-17 | 2021-07-29 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins |
-
2015
- 2015-02-12 GB GB201502305A patent/GB201502305D0/en not_active Ceased
-
2016
- 2016-02-12 DK DK16704223.3T patent/DK3256579T3/en active
- 2016-02-12 BR BR112017017286-0A patent/BR112017017286A2/en not_active Application Discontinuation
- 2016-02-12 FI FIEP16704223.3T patent/FI3256579T3/en active
- 2016-02-12 EP EP16704223.3A patent/EP3256579B1/en active Active
- 2016-02-12 HR HRP20231496TT patent/HRP20231496T1/en unknown
- 2016-02-12 ES ES16704223T patent/ES2962794T3/en active Active
- 2016-02-12 JP JP2017542900A patent/JP6879921B2/en active Active
- 2016-02-12 LT LTEPPCT/EP2016/053054T patent/LT3256579T/en unknown
- 2016-02-12 EA EA201791775A patent/EA035896B1/en not_active IP Right Cessation
- 2016-02-12 HU HUE16704223A patent/HUE064122T2/en unknown
- 2016-02-12 MY MYPI2017001125A patent/MY187486A/en unknown
- 2016-02-12 RS RS20231088A patent/RS64840B1/en unknown
- 2016-02-12 CA CA2976016A patent/CA2976016C/en active Active
- 2016-02-12 US US15/550,318 patent/US10758597B2/en active Active
- 2016-02-12 KR KR1020177025524A patent/KR102524594B1/en active IP Right Grant
- 2016-02-12 AU AU2016217801A patent/AU2016217801B2/en active Active
- 2016-02-12 CN CN201680021602.2A patent/CN107532158A/en active Pending
- 2016-02-12 CN CN202110810280.2A patent/CN113564150A/en active Pending
- 2016-02-12 SG SG11201706349YA patent/SG11201706349YA/en unknown
- 2016-02-12 WO PCT/EP2016/053054 patent/WO2016128559A1/en active Application Filing
- 2016-02-12 PL PL16704223.3T patent/PL3256579T3/en unknown
- 2016-02-12 MX MX2017010389A patent/MX2017010389A/en unknown
- 2016-02-12 PT PT167042233T patent/PT3256579T/en unknown
- 2016-02-12 SI SI201631755T patent/SI3256579T1/en unknown
- 2016-02-12 EP EP23180077.2A patent/EP4265719A1/en active Pending
-
2017
- 2017-07-27 ZA ZA2017/05114A patent/ZA201705114B/en unknown
- 2017-08-10 IL IL253939A patent/IL253939B/en active IP Right Grant
- 2017-08-11 CL CL2017002066A patent/CL2017002066A1/en unknown
- 2017-09-04 CO CONC2017/0009060A patent/CO2017009060A2/en unknown
-
2020
- 2020-02-17 US US16/792,747 patent/US11524057B2/en active Active
-
2022
- 2022-11-08 US US18/053,676 patent/US20230302100A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL253939A0 (en) | Cysteine protease | |
| IL253938A0 (en) | Cysteine protease | |
| AU364424S (en) | Watchcase | |
| AU364423S (en) | Watchcase | |
| SG11201705976UA (en) | Cryoneedle | |
| IL253635A0 (en) | Novel cyclopropabenzofuranyl pyridopyrazinediones | |
| PL3124119T3 (en) | Degerminator | |
| GB201506316D0 (en) | Novel peptide | |
| PL3458583T3 (en) | Improved-performance proteases | |
| EP3104705A4 (en) | Cathepsin cysteine protease inhibitors | |
| GB201417288D0 (en) | Cysteine labelling | |
| GB201516249D0 (en) | Liqui-glove | |
| GB201513444D0 (en) | Peptoid | |
| GB201502316D0 (en) | Bitcon technology | |
| GB201502073D0 (en) | HDEG technology | |
| RS63420B1 (en) | Peg-binder | |
| GB201617732D0 (en) | Corbel-Pro | |
| HUP1500342A2 (en) | Cylinder-head | |
| GB201520298D0 (en) | Thingy | |
| GB201506360D0 (en) | Novel peptide | |
| GB201516577D0 (en) | Project P | |
| GB201517693D0 (en) | Buggys | |
| GB201516942D0 (en) | Flightpal | |
| GB201516026D0 (en) | Rencu | |
| GB201515793D0 (en) | Dartboards |